Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term Preoperative Durvalumab in Early Small Triple-Negative Breast Cancer
2020-006106-23Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- May 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in triple-negative breast cancer (TNBC), sponsored by Gustave Roussy. Primary endpoint: Pathological complete response rate after 6 weeks of durvalumab. Started May 2021; status: active.
02
Drugs
durvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2020-006106-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006106-23.